Clinical trial · Observational
Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer
Follow-up Registration Management of Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer
NCT05383066CI-TRIAL-00058588unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To observe and explore the effect of anti-angiogenesis combined with PD-1/PD-L1 therapy in the real world on the survival prognosis of patients with advanced liver cancer, and to summarize the treatment experience of a wide range of people.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- those with anti-angiogenesis combined with PD-1/PD-L1 therapy
- description
- This study includes patients with advanced liver cancer who can benefit from anti-angiogenesis combined PD-1/PD-L1 treatment and observes the relationship between overall survival and their therpay.
Primary outcomes (1)
- measure
- Progression-Free Survival
- timeFrame
- 3-4 weeks
- description
- Progression-free survival (PFS) is defined as the time from random assignment in a clinical trial to disease progression or death from any cause.
Secondary outcomes (3)
- measure
- Overall survival
- timeFrame
- 3-4 weeks
- description
- Overall survival was defined as the duration from the date of diagnosis to death or last follow-up, with no restriction on the cause of death.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age: ≥ 18 years old, male or female; 2. Patients diagnosed with advanced liver cancer, including barcelona stage B, C or Chinese liver cancer guidelines stage IIa, IIb, IIIa, IIIb liver cancer patients; 3. doctors evaluate patients who can benefit from anti-angiogenesis targeted therapy; 4. patients voluntarily join the program and sign informed consent. Exclusion criteria: The above selection criteria are not met
References
Publications (0)
Data not yet available
No reference posted for this study.